Skip to main content
SpringerLink
Log in

Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystic carinii Pneumonia (PCP) before AIDS diagnosis in Italy

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

To determine the frequency and the determinants of use of antiretroviral drugs and prophylaxis for Pneumocystis carinii Pneumonia (PCP) among HIV-infected individuals before AIDS diagnosis, a questionnaire was sent to all physicians reporting at least one AIDS case during the first six months of 1994 to the Italian National AIDS Registry. Information on cases diagnosed between 1 January and 31 March 1995 was collected. Information was obtained for 878 (66.4%) of the 1323 persons with AIDS: 447 (50.9%) had received antiretroviral drugs and 343 (39.1%) PCP prophylaxis, whereas 303 cases (34.5%) had received both. Individuals who became aware of being HIV-positive shortly before AIDS diagnosis were less likely to have started antiretroviral therapy (adjusted odds ratio (AOR): 0.05, 95% CI: 0.03–0.09). Homosexual men and heterosexuals were more likely to begin therapy (AOR: 1.40, 95% CI: 0.83–2.37 and AOR: 1.79, 95% CI: 1.05–3.05, respectively) compared to injecting drug users. Individuals living in Southern Italy and foreigners were less likely to start therapy (AOR: 0.75, 95% CI: 0.49–1.16 and AOR: 0.40, 95% CI: 0.15–1.09, respectively) compared to those living in Northern Italy. Results were similar for PCP prophylaxis. Lack of awareness of HIV infection, HIV exposure category, and geographical area were the most important factors associated with treatment before AIDS diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–191.

    PubMed  Google Scholar 

  2. Volberding PA, Lagakos SW, Kock MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–949.

    PubMed  Google Scholar 

  3. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of Zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990; 112: 727–737.

    PubMed  Google Scholar 

  4. National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Public Health Service. State-of-the-Art Conference on Azidothymidine Therapy for Early HIV Infection. Am J Med 1990; 89: 335–344.

    Google Scholar 

  5. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral Therapy for Adult HIV Infected Patients. Recommendations from a State-of-the Art Conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients. JAMA 1993; 270: 2583–2589.

    PubMed  Google Scholar 

  6. Aboulker JP, Swart AM and the Concorde Coordinating Committee. Preliminary analysis of the Concorde trial. Lancet 1993; 341: 889–890.

    PubMed  Google Scholar 

  7. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995; 333: 401–407.

    PubMed  Google Scholar 

  8. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581–587.

    PubMed  Google Scholar 

  9. Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV–1 infection who received previous zidovudine therapy. Ann Intern Med 1993; 118: 762–769.

    PubMed  Google Scholar 

  10. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J Infect Dis 1995; 171 (Suppl. 2): 123–130.

    Google Scholar 

  11. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24–32.

    PubMed  Google Scholar 

  12. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT–3TC combination therapy. Science 1995; 269: 696–699.

    PubMed  Google Scholar 

  13. Delta Coordinating Committee. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zido47 vudine alone in HIV-infected individuals. Lancet 1996; 348: 273–278.

    Google Scholar 

  14. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC. January–February 1996.

  15. Bartlett JG. Protease Inhibitors for HIV infection. Ann Intern Med 1996; 124: 1086–1088.

    PubMed  Google Scholar 

  16. Lipsky JJ. Antiretroviral drugs for AIDS. Lancet 1996; 348: 800–803.

    PubMed  Google Scholar 

  17. Richman DD. HIV Therapeutics. Science 1996; 272: 1886–1888.

    PubMed  Google Scholar 

  18. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with Cd4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081–1090.

    PubMed  Google Scholar 

  19. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV–1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167–1170.

    PubMed  Google Scholar 

  20. Mellors JW, Kinsley LA, Rinaldo CR Jr, et al. Quantitation of HIV–1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573–579.

    PubMed  Google Scholar 

  21. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996; 2: 625–629.

    PubMed  Google Scholar 

  22. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996; 276: 146–154.

    PubMed  Google Scholar 

  23. Centers for Disease Control: Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989; 38 (Suppl.5): 1–9.

    Google Scholar 

  24. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932–944.

    PubMed  Google Scholar 

  25. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection. Recommendations for prophylaxis against Pneumocystis carinii Pneumonia for persons infected with Human Immunodeficiency Virus. J Acquir Immune Defic Syndr 1993; 6: 46–55.

    Google Scholar 

  26. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with Zidovudine. JAMA 1994; 271: 1088–1092.

    PubMed  Google Scholar 

  27. Communicable Disease Report. The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: Projections using data to the end of dy1994. CDR review 1996; 6: R1–R24.

    Google Scholar 

  28. Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G, and the HIV Italian Seroconversion Study Group. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. AIDS 1997; 11: 461–467.

    PubMed  Google Scholar 

  29. Centro Operativo Aids, Istituto Superiore di Sanità. Aggiornamento dei casi di AIDS notificati in Italia al 31 Dicembre 1995. Notiziario Ist. Super. Sanità 1996; 9; 4 (Suppl. 1) (in Italian).

    Google Scholar 

  30. Ancelle-Park RA. Expanded European AIDS case definition. Lancet 1993; 341: 441.

    Google Scholar 

  31. Breslow NE, Day NE. The analysis of case-control studies. In: Statistical methods in cancer research, vol. 1. Lyons: IARC Scientific Publication, 1980.

    Google Scholar 

  32. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, Inc., 1989.

    Google Scholar 

  33. Phillips AN, Smith GD, Johnson MA. Will we ever know when to treat HIV infection? BMJ 1996; 313: 608–610.

    PubMed  Google Scholar 

  34. Solomon L, Vlahov D, Astemborski J, Galai N, Graham NMH, Nelson KE. Factors associated with initiation of zidovudine in a cohort of injection drug users. J Drug Issues 1995; 25: 225–233.

    Google Scholar 

  35. D'Arminio Monforte A, Mainini F, Musicco M, et al. Impact of treatment and prophylaxis on presentation and survival of patients with AIDS in Milan. Lancet 1995; 346: 1488.

    Google Scholar 

  36. Porter K, Wall PG, Evans BG. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ 1993; 307: 20–23.

    PubMed  Google Scholar 

  37. Crotti N. La migrazione sanitaria. Valutazione ed interpretazione del fenomeno: Problemi organizzativi ed assistenziali. In: La salute degli italiani: Rapporto 1991. Roma: La Nuova Italia Scientifica, 1991: 137–163 (in Italian).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro Operativo AIDS, Laboratory of Epidemiology and Biostatistics, Istituto Superiore di Sanità, Epidemiology Unit, Rome

    Pier Angela Napoli, Maria Dorrucci, Patrizio Pezzotti & Giovanni Rezza

  2. Centro di Riferimento Oncologico, Aviano

    Diego Serraino & Silvia Franceschi

  3. Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy

    Stefano Vella

Authors
  1. Pier Angela Napoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Dorrucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diego Serraino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrizio Pezzotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Silvia Franceschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stefano Vella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giovanni Rezza
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Napoli, P.A., Dorrucci, M., Serraino, D. et al. Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystic carinii Pneumonia (PCP) before AIDS diagnosis in Italy. Eur J Epidemiol 14, 41–47 (1998). https://doi.org/10.1023/A:1007400519792

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007400519792

Search

Navigation